对晚期慢性肝病患者进行代谢表型分析以更好地刻画肝硬化逆转
这项病例对照先导研究纳入81例代偿期晚期慢性肝病患者,在病因治疗至少24个月后比较44例逆转者与37例未逆转者的临床、遗传及代谢特征。结果显示肥胖、高肝硬度及GCKR rs1260326变异与纤维化逆转可能性降低相关,并发现33种循环标志物可区分逆转者,外部验证队列(n=30)确认其中14种。
要点
- 肥胖、高肝硬度及GCKR rs1260326变异与代偿期晚期慢性肝病纤维化逆转可能性降低相关。
- 肝组织转录组学显示脂质代谢相关通路在逆转者与未逆转者间存在差异。
- 33种循环代谢标志物可区分逆转者,外部验证确认14种,可能作为无创生物标志物。
核心结论
- 发现并验证了一组与纤维化逆转相关的脂质生物标志物,可能作为检测代偿期晚期慢性肝病纤维化逆转的无创生物标志物。
研究设计与样本
- 病例对照先导研究,纳入81例代偿期晚期慢性肝病患者,其中逆转者44例、未逆转者37例,病因治疗至少24个月。
- 使用外部验证队列(n=30)进行数据验证。
主要发现
- 在60例已知遗传变异基因分型的患者亚组中,肥胖(OR 0.267,95%CI 0.072-0.882;p=0.049)、高肝硬度(OR 0.960,95%CI 0.925-0.995;p=0.032)及GCKR变异rs1260326携带(OR 0.148,95%CI 0.030-0.773;p=0.019)与纤维化逆转可能性降低相关。
- 肝组织转录组学识别出区分逆转者与未逆转者的代谢通路,顶级通路与脂质代谢相关,尤其是脂肪酸、胆汁酸、磷脂、三酰甘油(生物合成)及肉碱穿梭。
- 在整个发现队列中测量上述通路内代谢物,鉴定出33种循环标志物可区分病因治疗后的逆转者与未逆转者。
- 验证队列确认了14种差异表达标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Regression of cirrhosis has been observed in patients with viral and non-viral etiologies of liver disease in whom the underlying cause of liver injury was effectively suppressed. However, the understanding of the factors contributing to reversibility of fibrosis and cirrhosis is limited. Our aims were to assess clinical factors, perform genotyping of known variants, and comprehensive metabolic phenotyping to characterize the regression of fibrosis in patients with compensated advanced chronic liver disease (cACLD). METHODS: In a case-control pilot study of 81 patients with cACLD, we compared individuals exhibiting histological or clinical evidence of cACLD regression ("regressors"; n = 44) with those showing no improvement ("non-regressors"; n = 37) after a minimum of 24 months of successful treatment of the cause of liver disease. Data were validated using an external validation cohort (n = 30). RESULTS: Regardless of the cause of cACLD, the presence of obesity (odds ratio [OR] 0.267 95% CI 0.072-0.882; p = 0.049), high liver stiffness (OR 0.960, 95% CI 0.925-0.995; p = 0.032), and carriage of GCKR variant rs1260326 (OR 0.148, 95% CI 0.030-0.773; p = 0.019) are associated with a reduced likelihood of fibrosis regression in a subgroup of 60 patients with ACLD genotyped for known genetic variants. Using liver tissue transcriptomics, we identified metabolic pathways differentiating regressors from non-regressors, with top pathways associated with lipid metabolism - especially fatty acids, bile acids, phospholipids, triacylglycerides (biosynthesis), and the carnitine shuttle. In the entire discovery cohort, we further measured metabolites within the defined pathways, which led to the identification of 33 circulating markers differentiating regressors from non-regressors after etiological therapy. The validation cohort confirmed 14 of the differentially expressed markers. CONCLUSIONS: We identified and validated a group of lipid biomarkers associated with regression of fibrosis that could be used as non-invasive biomarkers for detecting regression of fibrosis in cACLD. IMPACT AND IMPLICATIONS: Regression of cirrhosis/advanced chronic liver disease (ACLD) after removal of the underlying cause of liver injury has been observed in human cirrhosis. However, detailed characterization of ACLD regression remains an unmet need. In this study, we provide a comprehensive phenotyping of individuals likely to experience ACLD regression. While obesity, carriage of GCKR variant rs1260326 and high liver stiffness were associated with lower likelihood of regression of ACLD, a signature of circulating lipid metabolites enabled differentiation of regressors from non-regressors after effective etiologic therapy. The lipid signature we discovered and externally validated could be used as non-invasive biomarker to detect regression of fibrosis in patients with compensated ACLD.
引用
- Mendoza YP, Tsouka S, Semmler G, et al. Metabolic phenotyping of patients with advanced chronic liver disease for better characterization of cirrhosis regression. J Hepatol. 2024. PMID: 38944391. doi:10.1016/j.jhep.2024.06.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。